X-Chem's program comprises multiple novel OX₂R-specific small-molecule orexin-positive modulators. Orexia will develop these molecules, will conduct clinical trials with drug candidates derived from the compounds, and will retain exclusive global rights to commercialize any resulting products, according to the companies.

X-Chem received a license payment and is eligible for future payments based on the achievement of specified research and development milestones, as well as royalties on the sale of approved products.

NIH awards Boragen grant for antimalarial drug discovery
Boron-based discovery platform firm Boragen has received a phase I Small Business Innovation Research grant from the U.S. National Institutes of Health...

Reverie Labs, Roche to advance kinase drug discovery
Reverie Labs is partnering with Roche and Genentech to advance next-generation kinase inhibitors with the use of artificial intelligence.

GHO acquires X-Chem
Global Healthcare Opportunities (GHO) has acquired X-Chem, a biotechnology company that provides drug discovery services via DNA-encoded library technology.

Ligand, Roche to develop ion channel drug discovery platform
Ligand Pharmaceuticals and Icagen have expanded Icagen's license agreement with Roche to develop and commercialize small molecule ion channel modulators...